Takefumi Kimura

ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2014-2024
Publications (10 Years): 18

Top Topics

Tyrosine Kinase

Helicobacter Pylori

Top Venues

Alimentary pharmacology & therapeutics

Liver international : official journal of the International Association for the Study of the Liver

Clinical journal of gastroenterology

This page only lists publications with an associated author ORCID identifier.

Publications

Nobuharu Tamaki, Takefumi Kimura, Shun-Ichi Wakabayashi, Takeji Umemura, Masayuki Kurosaki, Rohit Loomba, Namiki Izumi
Long-term clinical outcomes in steatotic liver disease and incidence of liver-related events, cardiovascular events and all-cause mortality. Alimentary pharmacology & therapeutics (2024)
Takefumi Kimura
Advancements in the Treatment Landscape of Hepatocellular Carcinoma. Cancers 16 (5) (2024)
Nobuharu Tamaki, Takefumi Kimura, Shun-Ichi Wakabayashi, Takeji Umemura, Namiki Izumi, Rohit Loomba, Masayuki Kurosaki
Cardiometabolic criteria as predictors and treatment targets of liver-related events and cardiovascular events in metabolic dysfunction-associated steatotic liver disease. Alimentary pharmacology & therapeutics (2024)
Nobuharu Tamaki, Takefumi Kimura, Shun-Ichi Wakabayashi, Takeji Umemura, Namiki Izumi, Rohit Loomba, Masayuki Kurosaki
Editorial: Has MetALD met the presumption? Authors' reply. Alimentary pharmacology & therapeutics 60 (1) (2024)
Nobuharu Tamaki, Takefumi Kimura, Shun-Ichi Wakabayashi, Takeji Umemura, Namiki Izumi, Rohit Loomba, Masayuki Kurosaki
Editorial: Cardiometabolic criteria matters in MASLD-Authors' reply. Alimentary pharmacology & therapeutics (2024)
Takefumi Kimura
Advancements in the Treatment Landscape of Hepatocellular Carcinoma. Cancers 16 (5) (2024)
Nobuharu Tamaki, Takefumi Kimura, Shun-Ichi Wakabayashi, Takeji Umemura, Namiki Izumi, Rohit Loomba, Masayuki Kurosaki
Editorial: Has MetALD met the presumption? Authors' reply. Alimentary pharmacology & therapeutics (2024)
Nobuharu Tamaki, Takefumi Kimura, Shun-Ichi Wakabayashi, Takeji Umemura, Masayuki Kurosaki, Rohit Loomba, Namiki Izumi
Long-term clinical outcomes in steatotic liver disease and incidence of liver-related events, cardiovascular events and all-cause mortality. Alimentary pharmacology & therapeutics 60 (1) (2024)
Nobuharu Tamaki, Takefumi Kimura, Shun-Ichi Wakabayashi, Takeji Umemura, Namiki Izumi, Rohit Loomba, Masayuki Kurosaki
Editorial: Has MetALD met the presumption? Authors' reply. Alimentary pharmacology & therapeutics 60 (1) (2024)
Nobuharu Tamaki, Takefumi Kimura, Shun-Ichi Wakabayashi, Takeji Umemura, Masayuki Kurosaki, Rohit Loomba, Namiki Izumi
Long-term clinical outcomes in steatotic liver disease and incidence of liver-related events, cardiovascular events and all-cause mortality. Alimentary pharmacology & therapeutics 60 (1) (2024)
Takanobu Iwadare, Takefumi Kimura, Yusuke Nagata, Hiroshi Suzuki, Hideo Kunimoto, Hiroyuki Kitabatake, Ayako Seki, Yasuhide Ochi, Etsuo Hara, Takeji Umemura
A case of malignant peritoneal mesothelioma with a Fitz-Hugh-Curtis syndrome-like imaging finding. Clinical journal of gastroenterology (2023)
Taiki Okumura, Takefumi Kimura, Yu Hihara, Katsuaki Inoue, Atsushi Maruyama, Satoru Joshita, Takeji Umemura
Immune thrombocytopenic purpura in primary biliary cholangitis and localized cutaneous systemic sclerosis: case report and literature review. Clinical journal of gastroenterology (2023)
Takefumi Kimura, Takanobu Iwadare, Shun-Ichi Wakabayashi, Seema Kuldeep, Tomoyuki Nakajima, Tomoo Yamazaki, Daiki Aomura, Hamim Zafar, Mai Iwaya, Satoru Joshita, Takeshi Uehara, Sai P Pydi, Naoki Tanaka, Takeji Umemura
Thrombospondin 2 is a key determinant of fibrogenesis in non-alcoholic fatty liver disease. Liver international : official journal of the International Association for the Study of the Liver (2023)
Naoyuki Fujimori, Takefumi Kimura, Naoki Tanaka, Tomoo Yamazaki, Taiki Okumura, Hiroyuki Kobayashi, Shun-Ichi Wakabayashi, Yuki Yamashita, Ayumi Sugiura, Jonathan Pham, Sai P Pydi, Kenji Sano, Satoru Joshita, Takeji Umemura
2-Step PLT16-AST44 method: Simplified liver fibrosis detection system in patients with non-alcoholic fatty liver disease. Hepatology research : the official journal of the Japan Society of Hepatology 52 (4) (2022)
Fangping Jia, Xiao Hu, Takefumi Kimura, Naoki Tanaka
Impact of Dietary Fat on the Progression of Liver Fibrosis: Lessons from Animal and Cell Studies. International journal of molecular sciences 22 (19) (2021)
Takefumi Kimura, Naoki Tanaka, Naoyuki Fujimori, Tomoo Yamazaki, Takahito Katsuyama, Yuichi Iwashita, Jonathan Pham, Satoru Joshita, Sai P Pydi, Takeji Umemura
Serum thrombospondin 2 is a novel predictor for the severity in the patients with NAFLD. Liver international : official journal of the International Association for the Study of the Liver 41 (3) (2021)
Shun-Ichi Wakabayashi, Takefumi Kimura, Naoki Tanaka
Acute liver failure with severe steatosis induced by mushroom. Liver international : official journal of the International Association for the Study of the Liver 40 (9) (2020)
Masafumi Maruyama, Naoki Tanaka, Daisuke Kubota, Masayuki Miyajima, Takefumi Kimura, Koujiro Tokutake, Ryujiro Imai, Toru Fujisawa, Hiromitsu Mori, Yoshiaki Matsuda, Shuichi Wada, Akira Horiuchi, Kendo Kiyosawa
Vonoprazan-Based Regimen Is More Useful than PPI-Based One as a First-Line Helicobacter pylori Eradication: A Randomized Controlled Trial. Canadian journal of gastroenterology & hepatology 2017 (2017)
Satoru Joshita, Takeji Umemura, Minoru Nakamura, Yoshihiko Katsuyama, Soichiro Shibata, Takefumi Kimura, Susumu Morita, Michiharu Komatsu, Akihiro Matsumoto, Kaname Yoshizawa, Hiromi Ishibashi, Eiji Tanaka, Masao Ota
STAT4 gene polymorphisms are associated with susceptibility and ANA status in primary biliary cirrhosis. Disease markers 2014 (2014)